WO2026086730A1 - Forme cristalline d'enmétazobactam et son procédé de préparation - Google Patents

Forme cristalline d'enmétazobactam et son procédé de préparation

Info

Publication number
WO2026086730A1
WO2026086730A1 PCT/CN2025/128704 CN2025128704W WO2026086730A1 WO 2026086730 A1 WO2026086730 A1 WO 2026086730A1 CN 2025128704 W CN2025128704 W CN 2025128704W WO 2026086730 A1 WO2026086730 A1 WO 2026086730A1
Authority
WO
WIPO (PCT)
Prior art keywords
eutectic
crystal form
gallic acid
eutectic crystal
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/128704
Other languages
English (en)
Chinese (zh)
Inventor
徐西坤
丁兆峰
付强
高永宏
范传文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Pharmaceutical Co Ltd
Original Assignee
Qilu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Pharmaceutical Co Ltd filed Critical Qilu Pharmaceutical Co Ltd
Publication of WO2026086730A1 publication Critical patent/WO2026086730A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une forme cocristalline d'enmétazobactam et d'acide gallique, son procédé de préparation et son utilisation. Le co-cristal obtenu présente des propriétés physiochimiques telles qu'une bonne solubilité, une bonne stabilité et une faible hygroscopicité, et est approprié pour le développement de médicament.
PCT/CN2025/128704 2024-10-21 2025-10-20 Forme cristalline d'enmétazobactam et son procédé de préparation Pending WO2026086730A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202411471114.4 2024-10-21

Publications (1)

Publication Number Publication Date
WO2026086730A1 true WO2026086730A1 (fr) 2026-04-30

Family

ID=

Similar Documents

Publication Publication Date Title
JP7086118B2 (ja) L-オルニチンフェニルアセテートおよびその製造方法
US12209080B2 (en) Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof
RU2603138C1 (ru) Кристаллическая форма хидамида, способ ее получения и применение
AU2017321594A1 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
JP2024028460A (ja) 化合物の結晶形態及び化合物の結晶形態を生成する方法
US20250163055A1 (en) Polymorph of jak tyrosine kinase inhibitor and preparation method therefor
JP2019516804A (ja) ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
KR100679904B1 (ko) 피리미딘 뉴클레오시드 유도체의 결정
US12384784B2 (en) Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
WO2026086730A1 (fr) Forme cristalline d'enmétazobactam et son procédé de préparation
TW201917117A (zh) 一種炔基吡啶類脯胺醯羥化酶抑制劑的晶型及其製備方法
CN103059013A (zh) 达沙替尼一水合物的新晶形及其制备方法
KR101928987B1 (ko) 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
CN113045554A (zh) 一种非索替尼晶型及其制备方法
EP4674850A1 (fr) Forme cristalline du composé 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione et son procédé de préparation
WO2026067708A1 (fr) Formes cristallines de resmétirom, son procédé de préparation et son utilisation
WO2025167588A1 (fr) Forme cristalline de zipalertinib, procédé de préparation s'y rapportant et utilisation associée
JP2026048666A (ja) インドール化合物の固体形態、その調製方法及びその使用
TW202220983A (zh) Cdk9抑制劑的多晶型物及其製法和用途
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
TW202340184A (zh) Cdk9抑制劑的多晶型物及其製法和用途
WO2019105082A1 (fr) Forme cristalline de galunisertib, son procédé de préparation et son utilisation
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2015113314A1 (fr) Nouvelle forme cristalline de 3- (4-amino -1,3-dihydro -1-oxo -2 h-isoindole -2-yl) -2,6-pipéridinedione et procédé de préparation correspondant